Acute Coronary Syndrome
Conditions
Keywords
acute coronary syndrome, statins, LDL-C, intensive education
Brief summary
Among the patients with coronary heart disease, those with ACS (acute coronary syndrome) are extremely high-risk patients. Therefore, management outside hospital, especially the regular administration of drugs, is vital to prevent the recurrence of cardiovascular events. However, most patients often fail to stay on a long-term administration regimen, especially the administration of statins. According to the statistics, the average duration adhered with statin in patients with ACS is less than 3 months, use of statin at hospital discharge was only 80% and 65% in 6 month, with a very low LDL-C control rate (about 11% at 6 months), which poses a threat to the recurrence rate of cardiovascular events in patients with ACS. It was found in previous studies that there were many factors influencing patients' compliance, in which patients' refusing to take medicine accounted for a higher proportion. It suggests that patient had not recognized the importance of long-term administration. Therefore, it is extremely important for physicians to strengthen patient education and regular follow-up visits during disease management. Moreover, the effectiveness of patient education during chronic disease management has already been proved in some studies abroad, and the interventional effect of multiple patient education process outweighs that of single approach education. Thus, we intend to conduct a randomized and controlled study to explore the effect of multi-channel intensive patient education on LDL-C target achieving rate and statin adherence in patients with ACS in China.
Interventions
BEHAVIORALIntensive Education
Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level. Patient education: 1. Routine education at discharge. 2. 4 education brochures will be delivered to patients. 3. Calendar with healthy tips will be delivered to patients before discharge. 4. A follow-up brochure with medical expert letter. 5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week). 6. Telephone follow ups will be performed according to a standard communication document. At discharge, patients will be given a brochure for future follow up.
OTHERControl
Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion. Patient education: 1. Routine education at discharge. 2. A follow-up brochure without medical expert letter. At discharge, patients will be given a brochure for future follow up.
Sponsors
Fujian Medical University
The Second Affiliated Hospital of Harbin Medical University
Xi'an Jiaotong University
The Luhe Teaching Hospital of the Capital Medical University
Junbo Ge
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patients admitted to the hospital with a diagnosis of ACS including those for first consulting or with recurrence. The patient was prescribed atorvastatin (Lipitor®) by physicians in hospital; 2. The age of patient enrolled will be ≥18 years old; 3. The patient is able to understand and complete questionnaire. 4. The patients agree to accept follow-up visits, and willing to participate in patient education courses and sign informed consent form.
Exclusion criteria
1. The patient has contraindications to statins, such as active hepatic disease, patient has a history of intolerance or hypersensitivity to statins or has a history of prior rhabdomyolysis on a statin. 2. The patient who uses other statins except Lipitor® when discharged from the hospital; 3. Cardiac function class of the patient is class IV(NYHA); 4. The patient has a malignant tumor; 5. The patient has a severe arrhythmia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C target achieving rate | at Week 24 post-discharge |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LDL-C target achieving rate | at Week 12 post-discharge | — |
| the proportions of patients with statin persistence | at Week 12 post-discharge | — |
| statin compliance | at Week 12 post-discharge | — |
| the discontinuation reason of statin therapy | at Week 24 post-discharge | — |
| the difference of LDL-C control rate and statin compliance | at Week 24 post-discharge | To find the difference of LDL-C control rate and statin compliance between pre-specified sub-groups: PCI or non-PCI/male or female/age (≥65) or not/ having medical insurance or not/dyslipidemia history or not /MI (myocardial infarction) or UA (unstable angina)/different risk level according to TIMI/ patients for first consulting or patients with recurrence/ have received statin in the last 3 months or not. |
| the relationship of LDL-C target achieving rate and statin compliance | at Week 24 post-discharge | — |
Other
| Measure | Time frame |
|---|---|
| the major adverse cardiovascular events | at 24 weeks follow up |
Countries
China
Contacts
Primary ContactBingqing Huang
Outcome results
None listed